Bimatoprost
CAS No:
155206-00-1
Molecular Formula：
C25H37NO4
Molecular Weight：
415.57
Storage:
Store in a tightly closed container in a cool, dry，Protect from moisture and direct sunlight.
Download Product Documents
If documents are missing, please contact customer service.
Technical Data
| Description | White powder |
|---|---|
| Identification | By HPLC HNMR |
| Solubility | Very soluble in ethanol,methanol,sparingly to slightly |
| Water | < 0.5 % |
| Residue on Ignition | ≤0.1% |
| Heavy metals | ≤10PPM |
| Optical rotation | +33.0°~+37.0°( C=2.0,CH3ON) |
| Related substances | 15-keto and Bimatoprost ≤ 0.10% |
| Residue Solvent | Ethyl acetate ≤ 0.5% |
| Purity | ≥99.5% |
Description
Bimatoprost is a synthetic prostamide analog primarily acting as a selective prostaglandin F2α (FP) receptor agonist. In vitro, it increases aqueous humor outflow in cultured human trabecular meshwork and ciliary muscle cells, showing dose-dependent elevation of matrix metalloproteinase (MMP) activity at 10–100 nM. In vivo, bimatoprost lowers intraocular pressure (IOP) in ocular hypertensive and normotensive animal models. In rabbits, topical doses of 0.01–0.03% reduced IOP by 25–35% within 5 hours, sustained for 24 hours. In monkeys, 0.03% topical treatment produced a maximal IOP reduction of ~30% over 24 hours. Bimatoprost also promotes eyelash growth in rodents, increasing hair length and density by 20–40% after 4 weeks of daily application. These effects are consistent with its dual role in enhancing uveoscleral outflow and modulating hair follicle activity, supporting its clinical use in glaucoma, ocular hypertension, and hypotrichosis of the eyelashes.
Safety Information
GHS
Pictogram:
Signal Word:
Warning
Hazard Statements:
H361 : Suspected of damaging fertility or the unborn child.
Precautionary Statements:
P501 : Dispose of contents/ container to an approved waste disposal plant.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P405 : Store locked up.
References
1: Vagiakis I, Papadopoulou EP, Amaxilati E, Tsiropoulos GN, Konstas AG, Panos GD. Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. Drug Des Devel Ther. 2025 Jan 31;19:703-714. doi: 10.2147/DDDT.S506520. PMID: 39906697; PMCID: PMC11792881.
2: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Bimatoprost. 2024 Dec 15. PMID: 30000734.
3: Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem EC, Enaholo ES, D’Esposito F, Musa M. From Eye Care to Hair Growth: Bimatoprost. Pharmaceuticals (Basel). 2024 Apr 27;17(5):561. doi: 10.3390/ph17050561. PMID: 38794131; PMCID: PMC11124470.
4: Sirinek PE, Lin MM. Intracameral sustained release bimatoprost implants (Durysta). Semin Ophthalmol. 2022 Apr 3;37(3):385-390. doi: 10.1080/08820538.2021.1985145. Epub 2021 Sep 29. PMID: 34586961.
5: Deveau AP, da Silva FN, Ly TY, Hussain A. Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review. Orbit. 2023 Feb;42(1):73-80. doi: 10.1080/01676830.2021.1955392. Epub 2021 Jul 28. PMID: 34320913.
Reviews
There are no reviews yet.